No Data
No Data
Zhejiang Huahai Pharmaceutical Subsidiaries Get Regulatory Nod for Tumor Clinical Trial; Shares Down 3%
Zhejiang Huahai Pharmaceutical (SHA:600521) said subsidiaries Shanghai Huaotai Biopharmaceutical and Huabo Biopharmaceutical Technology (Shanghai) received the approval for a drug clinical trial on th
Zhejiang Huahai Pharmaceutical (600521.SH): HB0046 injection received drug clinical trial approval.
Zhejiang Huahai Pharmaceutical (600521.SH) announced that its subsidiary, Shanghai Huaotai Biomedical Pharmaceutical Co., Ltd. and Huabo Biomedical Pharmaceutical Technology (Shanghai) Co., Ltd., have received the Approval Notice for Drug Clinical Trial of HB0046 Injection issued by the National Medical Products Administration. Recently, the National Medical Products Administration has approved the clinical trial of the drug for late-stage solid tumors.
Here's What We Like About Zhejiang Huahai Pharmaceutical's (SHSE:600521) Upcoming Dividend
It looks like Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521) is about to go ex-dividend in the next two days. The ex-dividend date is one business day before the record date, which is the cut
Institutional investors and Shanghai-Hong Kong Stock Connect are teaming up to 'crazy buy' Zhejiang Huahai Pharmaceutical while Shandong is helping with the escape of Shenzhen Genvict Technologies, according to the Dragon-Tiger List.
Today, the top three net buy-ins on the Dragon and Tiger List are Shenzhen Genvict Technologies, Surfilter Network Technology, and Jiangsu Shagang.
Zhejiang Huahai Pharmaceutical (600521.SH): The drug registration certificate for amlodipine and olmesartan medoxomil tablets has been obtained.
On July 5th, Gelunhui reported that Zhejiang Huahai Pharmaceutical (600521.SH) recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the approval of the registration of the combination of Olmesartan Medoxomil and Amlodipine besylate tablets, which is used for the treatment of primary hypertension.
Huahai Pharmaceutical's H1 Profit to Jump Up to 38%; Shares Up 9%
Zhejiang Huahai Pharmaceutical (SHA:600521) expects to log a net profit attributable to shareholders of between 728 million yuan and 785 million yuan in the first half of the year, jumping up to 38% f
No Data